URC Swaziland reports Xpert TB diagnostic tool failure in pregnant women

“Your data is awesome!”

That was the first response from an audience member following Dr. Marianne Calnan’s presentation of data showing that GeneXpert, a diagnostic tool increasingly favored by TB screening and treatment programs for its ability to identify multi-drug and RIF-resistant TB, missed 100% of new TB cases in pregnant women in her study’s health facilities.

Dr. Calnan, who is URC’s Deputy Director of the USAID TB Care II project in Swaziland, also showed data demonstrating that the WHO’s 4 question screening missed about 85% of TB cases among the study cohort.

Following her presentation, Dr. Calnan answered questions from fellow TB researchers for nearly half an hour, an indication of the intense level of interest in the project’s findings. While there is a growing body of research demonstrating the efficacy of the GeneXpert test in the general population, there is very little data available on its use in pregnant women and new mothers, who research suggests are at an increased risk of TB.

Congratulations to Dr. Calnan and the TB Care II Swaziland team for their important findings and great presentation at the 47th Union World Conference on Lung Health.

For Dr. Calnan’s full presentation, click here.

Dr. Calnan, URC’s Deputy Director of the USAID TB Care II project, presents her team's findings at the 47th Union World Conference on Lung Health
Dr. Calnan, URC’s Deputy Director of the USAID TB Care II project presents her teams findings at the 47th Union World Conference on Lung Health
Date 
October 31, 2016
Authors 
Rebecca Oser, Director of Communications
Regions/ Countries